Unmet Cardiovascular Therapeutics Market to Hit $3.18 Billion by 2036 as Gene Therapy Drives 9.1% CAGR
Updated
Updated · futuremarketinsights.com · Aug 1
Unmet Cardiovascular Therapeutics Market to Hit $3.18 Billion by 2036 as Gene Therapy Drives 9.1% CAGR
3 articles · Updated · futuremarketinsights.com · Aug 1
Summary
$3.18 billion is the projected size of the unmet-need cardiovascular therapeutics market by 2036, up from $1.33 billion in 2026, according to the report.
Advanced therapies for heart failure and resistant hypertension are expected to drive that 9.1% annual growth, with broader demand also spanning atherosclerotic cardiovascular disease, cardiomyopathies and atrial fibrillation.
Gene therapy is forecast to hold a 44.4% share in 2026, while heart failure leads indications at 32.6%, helped by measurable hospital outcomes and an estimated 6.7 million U.S. adults living with heart failure.
Japan posts the fastest disclosed country growth at 10.0% CAGR, ahead of the UK at 9.7% and the U.S. at 9.1%, reflecting differences in specialist care pathways, reimbursement and monitoring capacity.
FDA draft guidance issued in June 2026 for cell and gene therapies underscores a central hurdle for wider adoption: companies and hospitals must show clear patient selection, long-term safety evidence and defined follow-up responsibility.
Why is Japan set to outgrow the US and Europe in unmet-need cardiovascular therapies, and what does that reveal about specialist care readiness?
Can gene and RNA therapies really transform heart failure care, or will weak long-term evidence and reimbursement barriers slow this USD 3.2 billion market?